There is now a large body of evidence suggesting that the decline in ovarian function with menopause is associated with spontaneous increases in proinflammatory cytokines. 
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I. Introduction
N ATURAL MENOPAUSE IS associated with a rapid decline in circulating estrogen (1) . There is now a large body of evidence suggesting that, apart from the loss of reproductive function, the decline in sex hormones has many implications for nonreproductive tissues (2, 3) . For example, it is well known that estrogen contributes to the maintenance of bone mass. Despite recent doubts arising from short-term placebo-controlled studies in women with established coronary artery disease, there is still substantial reason to believe that estrogen may prevent coronary heart disease in the long run. Because the average life expectancy for women in Western countries exceeds 80 yr and women spend more than a third of their lifetime in postmenopause, the possible implications of estrogen deficiency on the rates of cardiovascular disease and osteoporosis are of enormous public health importance.
There is no unifying mechanism that would be able to explain all consequences of menopause on the metabolism of organs as diverse as bone, blood vessels, or adipose tissue (4 -6) . However, menopause-triggered changes in the activity of proinflammatory cytokines are beginning to emerge as a common theme that may have a significant impact on the function of all of these tissues. The following review focuses on what is currently known about the mechanisms of the interactions between estrogen and proinflammatory cytokines and attempts to outline possible implications for bone and the cardiovascular system.
II. Evidence for Increases in IL-1, TNF-␣, and IL-6 after Natural or Surgical Menopause
Spontaneous increases in the expression and secretion of the proinflammatory cytokines IL-1, IL-6, and TNF-␣ with estrogen deficiency were first noted several years ago in ex vivo cultures of circulating monocytes (Refs. 7 and 8 and Fig.  1 ), bone marrow macrophages (9 -12) , and osteoblasts (13). Increases in these cytokines with estrogen deficiency are, however, subtle compared with the increases observed as a host reaction to infection or major tissue injury (14) . Efforts to directly demonstrate cytokine increases with estrogen deficiency in tissue samples in vivo (15, 16) or in circulation (17-20) have been less successful. Nevertheless, using extremely sensitive techniques, such as IL-6 promoter luciferase constructs, increases in IL-6 promoter activity have been observed in the spleens of ovariectomized transgenic mice harboring these constructs (21). Moreover, several authors have noted increases (22) or at least a trend for increases (23, 24) in circulating IL-6 and TNF-␣ (25) after natural or surgical menopause.
Estrogen deficiency has also been shown to enhance the responsiveness of cells toward some of these cytokines by up-regulating cytokine receptor numbers and cofactors of cytokine action, thus amplifying the effects of the cytokine increases. For example, in ex vivo bone marrow cultures of ovariectomized mice, the expression of both the ligand-binding subunit of the IL-6 receptor [glycoprotein (gp) 80] and the signal-transducing subunit of the IL-6 receptor (gp130) were found to be increased (26). In humans, elevated soluble IL-6 receptor (sIL-6R) concentrations in circulation have been observed after surgical and natural menopause (23, 27) . sIL-6R is derived from the extracellular domain of the 80-kDa receptor and is capable of presenting IL-6 to the signal-transducer gp130, thus enhancing cell responsiveness to IL-6. It is still unclear whether these changes in cell responsiveness are a direct consequence of estrogen deficiency or whether they are secondary to the increases in IL-6 concentration, because IL-6 is known to stimulate gp130 gene transcription (28). There is preliminary evidence that estrogen deficiency may also enhance the responsiveness to IL-6 through modulating IL-6 signaling pathways (29). For example, in multiple myeloma cells, 17-␤-E2 completely abolished IL-6-inducible cell proliferation by inducing mRNA expression of the protein inhibitor of activated signal transducer and activator of transcription 3 (30).
III. Effect of Estrogen Treatment on IL-1, IL-6, and TNF
Because withdrawal of estrogen is associated with increases in cytokine activity, administration of estrogen might be expected to cause corresponding decreases in cytokine activity. Indeed, E2 treatment inhibited IL-1␤ and TNF-␣ expression and/or release in osteoblast-like cells (31, 32), monocytes/macrophages (8, (33) (34) (35) (36) (37) , and whole-blood cultures (38). Likewise, E2 inhibited the release of IL-6 from a variety of cell species, including macrophages (37, 39), bone marrow cells (40), whole-blood cultures (38), bone marrow stromal cells, synoviocytes (41), osteoblasts (Refs. 42-45 and Fig. 2) , and endothelial cells (46 -48). E2 attenuated increases in circulating IL-6 levels in mice in vivo triggered by hemorrhage (49, 50). Estrogen-treated ovariectomized rhesus monkeys showed an attenuation of the peak ACTH level and the IL-6 response to an iv infusion of recombinant human IL-1 ␤ (51). Similar inhibitory effects of estrogen on cytokine responses and the hypothalamic-pituitary-adrenal axis toward inflammatory stimuli were observed in postmenopausal women (52). Moreover, serum IL-6 levels appear to be lower in postmenopausal women on hormonal replacement therapy (22, 53, 54) and in estrogen-treated ovariectomized mice (19) compared with untreated controls. Other endog- enous estrogens such as estrone, which is the predominant estrogen in the menopausal years (55), and environmental phytoestrogens (56) appear to share these repressive effects of E2 on IL-6 gene expression.
Complementary changes with estrogen treatment have been observed for several other components that determine cytokine activity, such as cytokine receptors and specific binding proteins. The latter are crucial for keeping proinflammatory cytokine activities in check by interfering with cytokine receptor binding (57). Estrogen treatment increased the expression of the decoy type II IL-1 receptor in bone marrow cells and osteoclasts, while decreasing the steadystate levels of the type I IL-1 signaling receptor (58). Downregulation of the expression of the IL-6 receptor and signaling proteins by E2 was reported for bone marrow stromal cells (26) .
Nevertheless, the relation between estrogen and these cytokines is far from being that simple. In fact, the existing literature is replete with seemingly contradictory data, because an equally large number of studies failed to demonstrate any effects of estrogen on the expression or protein concentrations of these cytokines. A lack of estrogen action has been reported for macrophages (59, 60, 61), bone marrow cells (45, 62, 63), bone marrow stromal cells/osteoblasts (31, 64 -66), vascular smooth muscle cells (67), or on circulating levels of these cytokines (27, 63, 68 -69). Even more puzzling, some researchers have even reported biphasic (70) or frankly stimulatory effects of estrogen on the release of IL-1, TNF-␣, or IL-6 from monocytes/macrophages (19, 71-75) and fibroblast-like synoviocytes (76). Similar conflicting data have been reported for the effects of estrogen on the concentration of circulating TNF-␣ (39), IL-1␣, and IL-6 (77).
These discrepancies are not readily explained by differences in species, cell type, time after menopause, estrogen concentrations, or culture conditions. They raise the hypothesis that there may be several distinct pathways by which estrogen may affect cytokine gene expression, eliciting either net increases or decreases in cytokine production, depending on the activation of these pathways in the individual cellular context. Alternatively, there may be some intrinsic or extrinsic coregulators of estrogen action that are able to switch the response from suppression to stimulation, again largely depending on the individual cellular context. Part of the discrepancies, particularly those involving in vivo studies, may also be due to pharmacological differences between hormonal replacement and endogenous estrogen secretion. There is no study as yet that would have reported spontaneous decreases in cytokine activity with natural menopause, suggesting that stimulatory effects of estrogen on cytokine production in nonreproductive tissues may perhaps only occur with nonphysiological conditions. For example, in a recent study, monocyte IL-6 secretion was inhibited by estrogen in healthy rats, but inhibition tended to be reversed under conditions of activated immune function (19) . Better comprehension of the complex effects of estrogen on cytokine production will largely depend on the success in unraveling the underlying mechanisms of these effects at the molecular level.
IV. Potential Mechanisms of the Interaction between
Estrogen and Proinflammatory Cytokines at the Molecular Level (Fig. 3) At present, it appears as though most, if not all, effects of estrogen on cytokine activity in nonreproductive tissues occur by activating the ER. There are two well-characterized intracellular ERs, -␣ and -␤ (78). The tripartite structure of the ERs is defined by a central sequence-specific DNA binding domain, an N-terminal constitutive activation function (AF)-1, and a C-terminal E/F domain (AF-2). In the best understood mode of action, or classical pathway, ERs function as ligand-dependent transcription factors. Ligand binding is thought to cause a conformational shift in helix 12 in the C-terminal AF-2 domain. This is followed by the dissociation of tissue-specific corepressors and association of coactivators that favor the binding to specific consensus regulatory sequences, referred to as estrogen response elements (EREs), located within the regulatory regions of target genes (79). The effects of estrogen on reproductive tissues are mediated this way. In contrast, the promoters of IL-1, IL-6, and TNF-␣ lack a classical ERE. Activation of the ER, therefore, is unlikely to result in a direct interaction with these promoters (43). Studies with the new class of selective ER modulators (SERMs) have provided further evidence for a different mode of interaction of the ER with target genes in nonreproductive tissues that is not mediated by a direct transcriptional effect of the ER (80 -82). Consistent with such ERE-independent actions of the ER, several interactions of the ER with other transcription factors have been discovered in the past few years, some of which may also be involved in the inhibitory effects of estrogen on proinflammatory cytokine activity.
A. Interactions between estrogen and the IL-6 gene
Nuclear factor-B (NF-B) has a key role as a coordinating element in the response of the body to situations of stress, infection, or inflammation. NF-B preexists in the cytoplasm of most cells in an inactive form bound to the inhibitory protein IB. On receipt of an appropriate signal, NF-B is released from IB and translocates to the nucleus where it can up-regulate the expression of IL-1, IL-6, TNF-␣, and other cytokines essential in an inflammatory response by binding to specific NF-B binding sites in the promoter regions of these genes (83). Some of these cytokines, e.g., IL-1 and TNF-␣, activate NF-B themselves, thus initiating an autoregulatory feedback loop.
The inhibitory action of the activated ER on binding of NF-B to the IL-6-gene is one of the best-examined examples for a cross-talk between ligand-activated ERs and proinflammatory transcription factors. Expression of IL-6 at inflammatory sites is largely controlled by NF-B (84). Antagonism of NF-B activity has been observed with many nuclear receptors, including the receptors for glucocorticoids (85, 86), androgens (87), progesterone (88), the RXR (89), and the peroxisome proliferator-activated receptor ␥ (90). There is also ample evidence that the p65 subunit of NF-B represses ER-␣-mediated transactivation (86). However, in some cells, this repression appears to be reciprocal, and E2 can in return block the ability of NF-B to bind to target sequences located within the regulatory regions of the IL-6 gene (44). These repressive effects of 17␤-E2 on NF-B activation have now been confirmed for a large number of different cell species, including astroglia cells (91), HeLa cells (92, 93), murine macrophages (94), human osteoblasts (44), human hepatoma HepG2 cells (95), and rat cardiac myocytes (96).
The cell type-specific manner in which this occurs is consistent with a cofactor-modulated process. Deletion analysis and the use of ER-␣/␤ chimeras suggest that in osteoblasts, the A/B domain of the ER containing AF-1 is essential for preventing NF-B-induced gene transcription (97). The exact mechanism by which the ER blocks NF-B-induced IL-6 expression is, however, not agreed upon (98, 99). The association between ER and NF-B may introduce conformational changes in both proteins that lead to the inability to bind DNA (98). Alternatively, the association may result in the formation of inactive complexes on the DNA by preventing the interaction with essential cofactors or the basal transcriptional machinery. The NF-B protein RelA (p65) can recruit histone acetyltransferase activity to the promoter through interactions with the p300 and cAMP response element binding protein-binding protein (CBP) coactivator proteins (100). A competitive mechanism for limiting amounts of CBP and other coactivators has been proposed for the interaction between NF-B and the GR to explain glucocorticoid-mediated inhibition of NF-B (101). A similar competition may be involved in the estrogen-mediated inhibition of NF-Binduced IL-6 transcription, because the ER also interacts with the p300 coactivator. In support of this hypothesis, Harnish FIG. 3 . Schematic presentation of the potential actions of estrogen on proinflammatory cytokine activity. The activated ER directly inhibits IL-6 and TNF-␣ gene expression via NF-B-and AP-1-dependent mechanisms. Estrogen also modulates the activity of NO via eNOS and iNOS, exerts direct and indirect antioxidative actions, and interferes with the activity of the hypothalamic-pituitary-adrenal (HPA)-axis and lymphocyte function. Membrane ERs may also be involved in cytokine regulation. Cytokines that have been shown to be directly and/or indirectly modulated by estrogen include IL-1, IL-6, TNF-␣, M-CSF, GM-CSF, OPG, and TGF-␤. 2, Stimulatory effects; Ќ, inhibitory effects.
et al. (95) showed that in HepG2 cells, ligand-bound ER-␣ decreased histone acetyltransferase activity required for NF-B transcriptional activity. CBP reversed NF-B inhibition, supporting the hypothesis that reduced NF-B function may occur by limiting the availability of this coactivator. Moreover, overexpression of p300 in human coronary smooth muscle cells significantly reduced the inhibitory effect of ER on RelA-dependent transcription in these cells (102). Nevertheless, some questions remain, because the latter effects were ligand dependent and may be explained by a direct inhibitory effect of p300 on ligand sensitivity (103).
In some cell species, estrogen may also act by modifying the expression of factors binding to the DNA or by altering nuclear translocation of NF-B. Thus, in a study by Sun et al. (104) , estrogen was observed to block the degradation of IB␣, suggesting that the inhibitory effect of estrogen on NF-B function may also be, in part, due to the sustained presence of the inhibitory subunit of NF-B.
It has been suggested that the effects of the ER on IL-6 transcription may extend beyond NF-B, because the transcription factor CCAAT/enhancer-binding protein (C/ EBP)␤ (nuclear factor-IL-6) has also been shown to interact with the human ER in vitro (44). Many immune response genes and acute-phase response genes contain both C/EBP␤ and NF-B sites, and cooperative interactions between nuclear factor-IL-6 and NF-B may play an important role in the expression of these genes (105). Indeed, studies in HeLa cells transiently transfected with a pIL-6/chloramphenicol acetyltransferase plasmid and an ER expression vector, suggested that, in addition to an intact NF-B binding site, estrogen repression of IL-6 responses requires the binding of C/EBPfamily factors to the C/EBP site of the IL-6 promoter (93). However, the need for C/EBP for the inhibitory effects of estrogen on IL-6 in HeLa cells was not confirmed by Galien and Garcia (98) in a second study.
Estrogen-induced down-regulation of IL-6 expression has been independently observed in cells that only express ER-␣ or ER-␤ (96, 106), suggesting that both receptor types are capable of repressing NF-B signaling to the IL-6 gene upon activation. Whether this may apply to all forms of the ER-␤ is not clear yet, because Bhat et al. (107) have identified a form of a human ER-␤ containing an N-terminal extension that attenuated cytokine-mediated NF-B activation in contrast to a receptor form lacking this N-terminal extension. In human osteoblastic U2-OS cells that were transiently or stably transfected with ER-␣ or ER-␤, ER-␣ was the major ER through which transcription of NF-B-regulated genes was inhibited, suggesting that the extent of estrogen-induced IL-6 suppression may depend on the cell-specific pattern of ER expression (97).
The described interaction between the ER and NF-B may also be relevant to the expression of other NF-B-regulated proinflammatory cytokine genes (108). However, because many of these interactions appear to be cell-and genespecific, extrapolations from the above findings to other cytokine genes are difficult to draw without detailed examination. This is illustrated by the observation that NF-B complexes cooperate with ER-␣ to recruit cofactors into the complex and thereby synergistically activate the serotonin-1A receptor promoter (109).
B. Interactions between estrogen and the TNF-␣ gene
The activator protein (AP)-1 site in the TNF-responsive element of the Ϫ125 to Ϫ82 region of the TNF-␣-promoter is thought to be critical for the ability of IL-1 and TNF-␣ to induce TNF-␣ gene expression. AP-1 consists of homodimers of Jun family proteins or heterodimers of the Jun family with Fos family proteins (110). Depending on the cellular context and the transcribed gene, estrogen has been shown to either activate (111-117) or suppress (118, 119) AP-1-mediated gene transcription. In monocytic cells, estrogen blocks AP-1-mediated transcription of the TNF-␣ gene. Interestingly, estrogen also repressed the collagenase promoter when cotransfected into the cells, despite the fact that estrogen is known to activate collagenase transcription in other cell types via an AP-1 element in the collagenase promoter. This clearly indicates that estrogen-mediated stimulation or repression of gene transcription at AP-1 sites occurs in a cellspecific fashion (120). Of note, soybean isoflavones are also capable of suppressing TNF-␣ transcription in monocytes by binding to the ER (121).
The direct interaction between the ER and the AP-1 site in the TNF-␣ promoter requires binding of the ER to other promoter-bound proteins, such as the GR-interacting protein 1 (121, 122), and the AF-2 surface in the ligand-binding domain of the ER (120, 121). This may explain why raloxifene, which prevents the formation of an active AF-2 surface, antagonized the AP-1-mediated repression of the TNF-␣ promoter (120, 122).
Estrogen may also suppress AP-1-dependent TNF-␣-transcription by inhibiting Jun expression and suppressing the Jun N-terminal kinase pathway. Binding of estrogen to ER-␤ in the murine RAW 264.7 monocytic cells reduced the activity of the Jun NH 2 -terminal kinase, diminished phosphorylation of c-Jun and JunD at their NH 2 termini, and resulted in a consecutive decrease in the ability of these nuclear proteins to autostimulate the expression of c-Jun and JunD genes, thus leading to lower production of c-Jun and JunD (123, 124).
Decreases in TNF-␣ transcription in monocytes were observed with transfection of both the estrogen ␣-and ␤-receptor, albeit the latter appears to be more efficient in suppressing TNF-␣ transcription (120, 123). There is increasing awareness of such a selective regulation of ER-␣ and -␤ mode and amplitude of gene transcription by different receptor ligands, as both receptors appear to have strong affinity preferences for particular coactivators (125). The manner by which the two different ERs are regulated is just about to be explored, but differential effects of ER-␣ and ER-␤ on both NF-B-induced IL-6 production (97) and AP-1-dependent TNF-␣ gene transcription may offer a glimpse at one of several possible mechanisms explaining the cell-specific differences in the effects of estrogen on cytokine production.
Until now, no direct molecular mechanism has been proposed for a direct suppressive effect of estrogen on IL-1 transcription. NF-B is a potent stimulator of IL-1 gene transcription (126), raising the possibility that repression of IL-1 transcription by estrogen may work through a similar mechanism as that implicated in the repression of IL-6 gene transcription. However, it is also possible that the increases in IL-1 activity with estrogen deficiency may be merely secondary to an increase in TNF-␣, as the two cytokines are known to stimulate the expression of each other (127, 128) and the secretion of the two cytokines is usually closely correlated. Consistent with this hypothesis, TNF-␣ neutralization blocked IL-1 production, whereas IL-1 neutralization did not block TNF-␣ (129). Likewise, in cell cultures prepared from neonatal calvariae, TNF-␣-stimulated IL-6 production was inhibited by 17␤-E2, whereas IL-1-induced IL-6 production was unaffected by 17␤-E2 (42).
C. Estrogen, nitric oxide (NO), and cytokines
NO may be another potential target through which estrogen may regulate cytokine activity. NO has been the focus of much attention in the last few years. As a diffusible universal messenger, it plays a central role in the pathogenesis of inflammatory diseases (130). NO is an extremely pleiotropic molecule, and there are many contradictory reports in the literature concerning its role as an anti-or proinflammatory agent. These inconsistencies may be due to the multiple cellular actions of this molecule, the level and site of NO production, and the redox milieu into which it is released (131). Estrogen causes rapid stimulation of NO production in endothelial cells (132, 133), osteoblasts (134), and monocytes (135). This is achieved through up-regulation of the activity of the constitutively expressed endothelial NO synthase (eNOS/NOS III) and does not appear to be associated with changes in eNOS mRNA or protein (136). Correspondingly, ER-␣-knockout mice have a significantly reduced basal release of NO in aorta (137). Moreover, plasma nitrate and nitrite levels, which are related to NO production, are decreased in a state of estrogen deficiency (16, 138, 139), and serum NO levels increase with estrogen replacement (140, 141) .
Determining the precise mechanism through which estrogen regulates eNOS activity is an active area of investigation (142). There is increasing evidence that at least part of the acute stimulation of eNOS enzymatic activity may be mediated by coupling of specific plasma membrane ERs to G␣ proteins (134, 143, 144). In human endothelial cells, the ER-␣ also appears to bind to the p85␣ regulatory subunit of PI3K, leading to the activation of protein kinase B/Akt (145, 146).
Interestingly, and emphasizing the complexity of estrogen actions on NO production, estrogen inhibits another form of NOS that is induced by IL-1 and TNF-␣ and is therefore called cytokine-inducible NO synthase [iNOS/NOS II (147-150)]. We still do not exactly understand the physiological implications of the differential effects of estrogen on the two NO synthase isoforms. However, the inhibitory effects of estrogen on iNOS activity might well contribute to its suppressive effects on proinflammatory cytokine activity (149).
The effects of NO on proinflammatory cytokines and cytokine-dependent tissue activities are mixed and may critically depend on cofactors in the cellular environment. Both stimulatory (151-157) and inhibitory effects (158 -166) on the expression and/or secretion or proinflammatory cytokines have been described. These dual effects are nicely illustrated by the differential effects of NO in bone tissue. iNOS-deficient mice exhibit profound defects of IL-1-induced osteoclastic bone resorption through abnormalities in the translocation of the p65 component of NF-B and in NF-B-DNA binding, suggesting that the iNOS pathway is essential for IL-1-induced bone resorption, which is again thought to play a major role in menopause-associated bone loss (167). In contrast, NO donors have been rather shown to reverse ovariectomy-induced bone loss in rats (168, 169) , and nitrate use appears to protect postmenopausal women against bone loss as effectively as estrogen use (140, 170) .
At present, there are no data that would prove any relevance of these changes in NO activity to cytokine production with menopause. Nevertheless, given the central role of NO as a cellular mediator, the differential effects of estrogen on eNOS and iNOS activity on the one hand, and the variable interactions between NO and cytokine activity on the other hand, may be part of the "Janus-faced" effects of estrogen on cytokine production that have been encountered in some of the described experimental models.
D. Direct antioxidant effects of estrogen
Free radicals are potent stimuli of NF-B-mediated proinflammatory cytokine expression. As estrogen has direct antioxidant effects in vitro and in vivo, increases in free radical production with the decline in estrogen concentrations may be another source of increase in cytokine production. In vascular tissue, increases in the oxidative modifications of molecules, such as low-density lipoproteins, after menopause may stimulate cytokine production by propagating the formation of cytokine-producing foam cells that are characteristic of early atherosclerotic lesions (171) .
The mechanisms of the antioxidant effect of estrogen are incompletely understood and may vary in different tissues. Estrogen might play an inhibitory role either in production and/or scavenging of reactive oxygen species, or in protecting the level of endogenous antioxidants. An ER-dependent inhibition of superoxide anion production in microglial cells has been linked to the activation of MAPK (172) . Direct antioxidative effects appear to be dependent on the A-ring hydroxyl group of the estrogen molecule, which acts as a highly effective electron donor and free radical scavenger. 3-Methoxyestrone, which lacks the phenolic hydroxyl group, does not interfere with free radical generation (102, 173). However, E2 may also affect the cellular antioxidant enzyme system that is necessary to maintain an optimal redox balance. Detoxification of superoxide anion and hydrogen peroxide, catalyzed by intracellular superoxided dismutase, catalase, and glutathione peroxidase enzyme activities, represents a major line of defense. Significantly lower glutathione peroxidase activity has been seen in blood samples from late menopausal women compared with that seen in premenopausal women (174 -176) . Some of the antioxidative properties of estrogen on the vessel wall also appear to be mediated through down-regulation of angiotensin-1 (AT1) receptor gene expression. Up-regulation of AT1 receptor expression with estrogen deficiency is thought to be a predominant source of free radical production in the vasculature. Indeed, increases in the generation of superoxide radicals in the vessel wall with ovariectomy in the rat can be normalized by AT1 receptor antagonists (177-179).
The impact of these antioxidative effects of estrogen on cytokine production has received little attention so far. Many of the antioxidative effects of estrogen have been observed at supraphysiological levels, but there are some data showing that these effects may also be relevant at physiological estrogen levels (180) . For example, 17␤-E2 inhibited in vitro vascular smooth muscle cell proliferation via a nongenomic antioxidant mechanism (181) . 17␤-E2, but also its stereoisomer 17␣-E2, dose dependently and receptor independently inhibited reactive oxygen species generation in cytomegalovirus-infected smooth muscle cells and the consecutive increases in NFB-activity. These effects occurred at physiological estrogen concentrations (102).
E. Rapid nongenomic actions
In a variety of cell types, E2 exerts rapid nongenomic actions that appear to be mediated by plasma membrane ERs (182) . For example, E2 rapidly activates MAPK in endothelial cells (183) and in fibroblasts that have been transfected with cDNA clones encoding either ER-␣ or -␤ (184) . Estrogen also rapidly activates early growth response gene-1 expression in cardiomyocytes via ERK 1 and 2 (185) . These rapid effects of estrogen trigger several interactive signal transduction pathways that involve the PKC and PKA pathways as well as MAPK and resemble the effects of the more traditional membrane growth factor receptors. These pathways have the potential to enhance (186 -193) or inhibit (194) the expression of IL-1, IL-6, and/or TNF-␣, depending on the cellular context. The relevance of these estrogen membrane receptors for estrogen actions is just about to be explored, but it is possible that the stimulatory effects of estrogen on the production of proinflammatory cytokines that have been observed in some in vitro settings may be in part attributable to rapid estrogen actions and to membrane-receptor-mediated effects.
F. Effects of estrogen on lymphocytes
Of considerable interest both with respect to postmenopausal changes in bone metabolism and vascular function is the action of estrogen on lymphocyte function (195, 196) . Alterations in T cell subsets have already been described several years ago in women with postmenopausal osteoporosis (197, 198) . A recent study by Cenci et al. (199) suggested that the increase in TNF-␣ production in the bone marrow of ovariectomized mice may, at least in part, originate from activated T cells. Remarkably, this appeared to be due to the increase in the number of TNF-␣-producing T cells, not to an increase in TNF-␣ gene expression. The expansion of the T lymphocyte pool in bone marrow after loss of ovarian function may thus be an important indirect mechanism for increases in proinflammatory cytokine concentration. In line with this, the inhibitory effect of estrogen on TNF-␣ production in an animal model of experimental autoimmune encephalomyelitis appears to be predominantly due to a reduction in the number of proinflammatory cytokine producing T cells in the central nervous system (200) .
Estrogen deficiency is also associated with an increase in pre-B lymphopoiesis in bone marrow (201) (202) (203) (204) (205) . Vice versa, B-lineage differentiation in highly purified early pro-B cells was abrogated when the cells were treated with E2 (195) . In a mouse model of systemic lupus erythematosus, estrogen treatment altered the maturation of splenic B cell subsets with a diminished transitional population and an increase in marginal zone B cells (206) . As cell-to-cell interactions between lymphocytes and mesenchymal cells greatly affect the production of IL-6 by mesenchymal cells (207, 208) , the postmenopausal increases in lymphopoiesis may not only affect TNF-␣ secretion, but IL-6 synthesis as well.
At present, it is difficult to judge which may be first: the rise in proinflammatory cytokines or the enlargement of the activated lymphocyte pool. Arguing for the latter, both T and B cells express ERs, and estrogen deficiency may remove some direct restrictions imposed on lymphocyte proliferation and function. Alternatively, the increases in lymphocyte number and function may predominantly be the result of the increased availability of lymphocyte stimulators after menopause. RANKL, a member of the TNF ligand family whose interactions with estrogen will be described in Section V in more detail, is crucial for lymphocyte development. As the activity of RANKL is up-regulated by estrogen deficiency, this may in turn promote T and B cell development and activation (209) . Kanematsu et al. (210) reported that in ovariectomized mice, increases in pre-B cells were abolished by the administration of the cyclooxygenase (COX) inhibitor indomethacin. This suggests that RANKL-induced increases in pre-B cells may be in part mediated by increased PGE 2 levels. Administration of a neutralizing antibody against IL-6 also has been shown to prevent ovariectomy-induced increases in the number of several hematopoietic progenitors in the bone marrow of mice (211). Mechanisms that involve the interaction between matrix proteins, such as osteopontin and lymphocyte function, may potentially play a role as well (212).
G. Central interactions between the gonadal axis and inflammatory processes
Apart from direct cellular interactions between estrogen and cytokines at the molecular level, several menopauserelated changes in cell and tissue function have the potential to indirectly affect proinflammatory cytokine activity, although the relevance of these interactions is largely unknown at the present time. For example, estrogen is known to alter the hypothalamic-pituitary-adrenal axis through modulating the release of both hypothalamic and pituitary peptides, such as PRL (213) and GH, which in turn may modify immune responses and cytokine secretion (214). There are many other reciprocal interactions between the hypothalamic-pituitary-adrenal axis and immune-mediated inflammatory processes on the one hand and the gonadal axis on the other hand, which may potentially contribute to changes in inflammatory parameters with menopause. Estrogen directly enhances CRH gene expression and stimulates the central noradrenergic system, thereby positively affecting the two principal components of the stress system. (215). This may be associated with a suppression of the immune-inflammatory reaction and a shift from the T helper cell 1 to the T helper cell 2 profile in lymphocytes (216). It may also, in part, explain the preponderance of some autoimmune disorders in women as compared with men.
H. Changes in visceral fat with menopause
Women tend to accumulate visceral fat with menopause. This appears to involve an estrogen-dependent mechanism of reduced energy expenditure (217-219) and can be prevented by hormonal replacement therapy (220, 221). Although still speculative at the present time, adipose tissue might turn out to be a significant source of increased proinflammatory cytokines in postmenopausal women. Indeed, there is increasing evidence that adipose tissue is a major determinant of circulating IL-6 (222). As adipocytes from visceral adipose tissue release 2-3 times more IL-6 than those from the sc depot (223), even small increases in visceral fat with menopause might have a large impact on circulating IL-6 levels. In accordance with this hypothesis, Straub et al.
(54) observed a positive association between body mass index and serum IL-6 only in postmenopausal women, and this relationship was lost among women with hormone replacement. It appears that to some extent, IL-6 may in return increase estrogen synthesis in adipose tissue by stimulating the aromatase activity and, thus, the conversion of C19 androgenic steroids to estrogen (224). As adipose tissue is the major site of estrogen biosynthesis in postmenopausal women, this may serve as a negative feedback mechanism to limit IL-6 increases.
V. Effects of Estrogen on RANKL and Osteoprotegerin (OPG)
RANKL is a recently discovered member of the TNF superfamily. It is a membrane-associated factor that is expressed in a variety of cell species, including osteoblast/ stromal cells, endothelial cells, and lymphocytes. As a result of its independent discovery by several investigators, it is also known as TNF-related activation-induced cytokine, OPG ligand (OPG-L), and osteoclast differentiation factor (225, 226). RANKL exerts its effects through binding to RANK, a TNF receptor family member. RANK is also known as osteoclast differentiation and activation receptor. The biological activity of RANKL is neutralized by binding to OPG, another member of the TNF receptor superfamily. OPG is also known as osteoclastogenesis inhibitory factor, follicular dendritic cell-derived receptor-1, or TNF receptor-like molecule 1. OPG does not contain a transmembrane domain and acts as a soluble receptor.
RANKL and OPG have emerged as essential mediators of proinflammatory cytokines on osteoclastogenesis and lymphocyte maturation. RANKL-and RANK-deficient mice have a complete block in osteoclast development and show significant alterations in both immune cells and immune cell organs with a lack of lymph node development (227, 228). Moreover, several studies have implicated OPG in the regulation of vascular homeostasis (229 -230).
Estrogen dose dependently increased levels of OPG mRNA and protein in human osteoblastic cells (231) and stromal cells (232). Cotreatment with the antiestrogen ICI 182,780 abrogated these effects completely, demonstrating that they are ER mediated. In the mouse stromal cell line ST-2, enhanced induction of OPG expression was only observed in ER-␣-overexpressing cells, but not in ER-␤-transfected cells, indicating that, at least in some cell species, the stimulatory effects of estrogen on OPG are dependent on ER-␣ (233). Estrogen deficiency results in decreased OPG expression in bone, whereas estrogen replacement therapy prevents it (234). In accordance with these findings, postmenopausal women who use hormone replacement therapy were reported to have higher circulating OPG levels than those without hormone replacement (235). Apart from its direct effect on OPG synthesis, estrogen may indirectly block RANKL activity by limiting the availability of the major RANKL stimulators IL-1, IL-6, and TNF-␣ (236). However, IL-1-␣ and TNF-␣ are known to stimulate OPG secretion as well (237-240). RANK expression itself appears to be unaffected by estrogen deficiency, but estrogen deficiency may enhance RANK signaling in monocytes by down-regulating RANK-induced Jun N-terminal kinase 1 activity (241).
VI. Effects of Estrogen on Other Cellular Mediators Relevant to Inflammatory Processes

A. Effects of estrogen on TGF-␤
TGF-␤ plays an important role in tissue recycling and tissue repair in response to injury. It exerts a large number of suppressive effects on inflammatory processes, ranging from the suppression of the growth and differentiation of hematopoietic precursor cells to inhibition of proliferation and apoptosis of immunocompetent cells. TGF-␤ thereby often antagonizes the effects of proinflammatory cytokines. The essential role of TGF-␤ in suppressing inflammatory processes is impressively demonstrated by the appearance of massive infiltrations of inflammatory cells in several organs of mice deficient in TGF-␤1 activity (242-244).
Findings that estrogen positively affects TGF-␤ function have been very consistent for various tissues. Estrogen stimulates TGF-␤ expression and/or production by osteoclasts (245, 246), osteoblasts (247, 248), vascular smooth muscle cells (249), and fibroblasts (250). Transdermal 17␤-E2 increased serum levels of TGF-␤1 in postmenopausal women (251). With the exception of a single study (252), ovariectomized rats were observed to have lower protein and mRNA levels of TGF-␤1 in bone tissue compared with sham-operated rats (253-255). Interestingly, in contrast to rats, whose capacity for bone remodeling is limited and in whom the primary effects of estrogen on TGF-␤ production are likely to predominate, estrogen deficiency in humans is associated with an increase in skeletal TGF-␤, and this increase can be prevented by hormone replacement therapy (256). However, this is most likely a consequence of the reactive increases in bone formation and not a direct effect on TGF-␤ expression.
The stimulatory effects of estrogen on TGF-␤ activity are also ERE independent and can be mimicked by the SERMs tamoxifen and raloxifene (246, 248, 257). Yang et al. (248) demonstrated a direct interaction of the ER with a sequence in the TGF-␤3 gene promoter termed "raloxifene response element," which did not require the DNA binding domain of the ER. Astonishingly, activation of TGF-␤3 transcription was also observed with the pure ER antagonist ICI 164,384 (248), but this was not confirmed in another study (245).
B. Effects of estrogen on PG synthesis
COX is the key step in the conversion of arachidonic acid to a series of bioactive prostanoids. Two COX genes have been identified: a constitutive form (COX-1), which is expressed ubiquitously, and a second form (COX 2), which is highly inducible in response to proinflammatory cytokines (258). COX 2 expression is greatly elevated in both acute and chronic inflammation. PGE 2 is one of the most abundant COX metabolites. Estrogen deficiency increased PGE 2 concentrations in ex vivo cultures of human and rat bone marrow cells (12, 259) and in organ cultures of calvariae from ovariectomized rats (260). Postmenopausal women also excrete larger amounts of urinary PGE 2 compared with premenopausal women (261). Conversely, E2 inhibited PGE 2 production in stromal cells and monocytes (259, 261-263).
At present, there is no evidence for a direct inhibitory effect of estrogen on COX activity. Rather, estrogen increases the release of another COX product, PGI 2 , by vascular endothelium (264 -266). It is likely that the increased production of PGE 2 with menopause is predominantly due to the upregulation of its major cytokine inducers. This is supported by the finding that IL-1 receptor antagonist (IL-1ra) and anti-IL-1␣-neutralizing antibody were able to decrease exaggerated PG production and COX-2 expression in cultured neonatal mouse calvariae when stimulated with bone marrow supernatants from ovariectomized mice (259).
C. Effects of estrogen on macrophage colony-stimulating factor (M-CSF) and granulocyte-macrophage-colony stimulating factor (GM-CSF)
GM-CSF and M-CSF control the production, maturation, and function of granulocytes and monocyte-macrophages (267). Increases in GM-CSF activity were observed after surgical menopause in ex vivo cultures of peripheral blood mononuclear cells (7) . Bone marrow cells from women who had discontinued estrogen replacement shortly before aspiration or who were within 5 yr of natural menopause also secreted more GM-CSF than bone marrow cells from premenopausal women (12). As with PG production, the increases in GM-CSF with estrogen deficiency may be predominantly mediated by IL-1 and TNF-␣. However, other mechanisms must be involved as well, as the increase in GM-CSF production in mononuclear cells from ovariectomized women was very rapid and preceded the increase in IL-1 and TNF (7) .
Estrogen also down-regulates membrane-bound and soluble M-CSF. Whereas the expression of membrane-bound M-CSF on bone marrow cells is directly inhibited by estrogen (268, 269), down-regulation of soluble M-CSF secretion by estrogen may involve the differentiation of stroma cell precursors toward a mature phenotype characterized by a lower production of soluble M-CSF. Vice versa, estrogen deficiency increases the production of soluble M-CSF in bone marrow by an IL-1-and TNF-mediated expansion of a stromal cell population that produces larger amounts of soluble M-CSF (34, 270).
VII. Implications for Postmenopausal
Bone Loss (Fig. 4) 
A. Impact of cytokine changes with estrogen deficiency on osteoclastogenesis
There is progressive loss of bone tissue after natural or surgical menopause, leading to increased fractures within 15-20 yr from the cessation of ovarian function (271). ERs have been detected in many cells that reside in bone tissue (272-278), suggesting that menopause may have direct consequences on cytokine secretion by cells located within the bone microenvironment. Bone marrow cells of the monocyte/macrophage lineage are believed to be the major source of the postmenopausal increases in TNF-␣ and IL-1 secretion in bone tissue (279). However, in the past few years it has been increasingly recognized that activated T cells are also an important source of increased TNF-␣ production in the bone marrow after menopause (195, 196, 209, 280 -283) . In contrast, stromal cells/osteoblasts are considered to be the major producers of IL-6 in bone tissue (284).
Proinflammatory cytokines are among the most powerful stimulants of bone resorption known. They directly and through the stimulation of other local factors intervene with every single step in osteoclastogenesis that determines the rate of bone resorption, from the proliferation and differentiation of the early osteoclast precursor cell to the resorption capacity and the lifespan of the mature osteoclast (9, (285) (286) (287) (288) (289) (290) (291) (292) (293) (294) (295) (296) (297) (298) (299) (300) (301) . The first step in osteoclastogenesis that determines the rate of bone resorption is the proliferation of osteoclast precursor cells. In fact, a major consequence of estrogen deficiency is the expansion of the pool of osteoclastic precursor cells in the bone marrow. Loss of ovarian function is permissive for the expression of the major cytokines that directly stimulate early osteoclast precursor proliferation, i.e., M-CSF, GM-CSF, and IL-6 (289, [301] [302] [303] [304] [305] [306] [307] . Spontaneous increases in these cytokines may be further enhanced by the parallel increases in IL-1 and TNF-␣ with menopause, which are potent stimulators of M-CSF, GM-CSF (292, 298, 308 -311) , and IL-6 (64, 286, 306, 312-314). On the response side, these favorable changes in the cytokine environment with respect to osteoclast progenitor proliferation are met by complementary increases in the responsiveness of the osteoblast/ stromal cells to IL-6 by up-regulation of the IL-6 receptor and its signal transduction unit gp130 (26).
Because estrogen is a potent stimulator of OPG production (237) and suppresses M-CSF production, loss of estrogen would also be expected to promote the signaling and gene expression cascade that leads to the differentiation of osteoclast progenitors to mature osteoclasts. A decrease in OPG production with estrogen deficiency is bound to increase the ratio of RANKL/OPG activity. It thus facilitates the binding of RANKL-expressing osteoblast/stromal cells and lymphocytes to osteoclast progenitors as the key signal for initiating osteoclast differentiation (227, [315] [316] [317] [318] [319] . Estrogen deficiency is associated with the loss of inhibitory effects on a closely interrelated network of cytokine stimuli that are suited to tip the balance of RANKL-to-OPG production further toward increased RANKL activity. In particular, PGE 2 , which increases RANKL expression and decreases OPG expression in osteoblastic/stromal cells (240, 320, 321), may be involved in the increase in the expression of RANKL in bone marrow pre-B cells from ovariectomized mice, as the increase could be mimicked by PGE 2 and was abolished by indomethacin (210, 322). The PGE 2 -induced increases in the RANKL/OPG ratio with estrogen deficiency may again only be a consequence of increases in monocyte and T cell-derived IL-1 and TNF-␣ secretion (238, 318, (323) (324) (325) (326) . Although the data are still somewhat conflicting (226, 237, 239, 327), IL-6 also appears to contribute to this up-regulation of RANKL activity in estrogen-deficient osteoblastic cells (318, 328) .
Both TNF-␣ (316, 318, 329, 330) and PGE 2 (331) may have a direct, RANKL-independent effect on osteoclast differentiation. This effect may be small compared with that of RANKL, but it may be important for potentiating RANKLinduced osteoclast formation (332). Indeed, it has been proposed that because minuscule amounts of RANKL are sufficient to maximally stimulate osteoclastogenesis, RANKL-independent effects may be the true rate-limiting steps of increased osteoclast differentiation with menopause (332).
Whereas all of the consequences of estrogen deficiency on proinflammatory cytokine activity described so far are clearly synergistic with respect to osteoclast formation and strongly support a major role of these cytokines in postmenopausal bone loss, the role of TGF-␤ is more ambivalent. Proliferation of osteoclast progenitors may be facilitated by the relative decline in TGF-␤ activity with estrogen deficiency, as TGF-␤ has been shown to be a major inhibitor of osteoclast generation (333, 334). Relative decreases in TGF-␤ with menopause may also contribute to the increases in the RANKL/OPG ratio with estrogen deficiency (236, 326, 335). On the other hand, TGF-␤ has recently been observed to be essential for the differentiation of osteoclast precursors cells into osteoclasts (336 -338). Moreover, TGF-␤ has been described as both stimulating (339 -341) and inhibiting (73, 342, 343) proinflammatory cytokine production.
IL-1, TNF-␣ (344, 345), and PGE 2 (346) may not only promote osteoclast generation, but they also appear to stimulate mature osteoclasts to perform more resorption cycles via modulation of RANKL activity (347). IL-1 (318, 329, 348, 349) and IL-6 (350) also directly enhance osteoclast activity by RANKL-independent mechanisms. Finally, increases in IL-1 (351, 352), M-CSF (353), RANKL (225), and a relative decrease in TGF-␤ (246) may directly extend the lifespan of the osteoclast by inhibiting osteoclast apoptosis.
In premenopause, variations in bone resorption are usually compensated by appropriate changes in bone formation. This is thought to be the result of locally released anabolic growth factors, such as TGF-␤ (354) and IGFs (355). Efforts to compensate the increased bone resorption are also evident with estrogen deficiency (256) but obviously do not suffice to achieve a neutral bone balance. Thus, depending on the perspective, postmenopausal bone loss may also be viewed as resulting from inadequate bone formation. It is well known that proinflammatory cytokines have potent effects on osteoblast function. Both TNF-␣ and IL-1 inhibit collagen synthesis in osteoblasts (299, 356 -361) and stimulate or inhibit bone cell proliferation, depending on the experimental systems employed (325, 357, 362-365). Both TGF-␤ and PGE 2 FIG. 4. Overview of the multiple interactions by which cytokines and estrogen regulate bone resorption. The arrows indicate stimulatory (2) or inhibitory (Ќ) effects of a cytokine on the synthesis of another cytokine or on a particular step in osteoclastogenesis. Macrophages (IL-1 and TNF-␣), lymphocytes (TNF-␣ and RANKL), and stromal cells/osteoblasts (IL-6, TGF-␤, RANKL, M-CSF, GM-CSF, and PGE 2 ) are thought to contribute to the increased cytokine production in the bone microenvironment with estrogen deficiency. M-CSF, GM-CSF, and IL-6 facilitate osteoclast precursor proliferation. RANKL, TNF-␣, PGE 2 , and TGF-␤ participate in the differentiation of osteoclast precursors into mature osteoclasts. RANKL, IL-1, and IL-6 directly stimulate the bone resorbing activity of the mature osteoclast. IL-1, M-CSF, RANKL, and TGF-␤ modulate osteoclast apoptosis. IL-1, TNF-␣, PGE 2 , and TGF-␤ also have potent effects on osteoblast function. Most cytokines are stimulated or inhibited by other cytokines, thereby creating a network of synergistic cytokine actions, which ultimately lead to increased bone resorption. OB, Osteoblast/stromal cell; L, lymphocyte; M, monocyte/macrophage. are potent stimulators of bone formation (366, 367). However, the relevance of postmenopausal changes in these cytokines with respect to bone formation has been much less explored compared with bone resorption.
B. Evidence for an essential role of proinflammatory cytokines in bone loss with estrogen deficiency
There is now compelling evidence from studies in mice and rats that changes in cytokine activity with estrogen deficiency are indeed essential for the bone loss that is observed in these animals. Mice insensitive to IL-1 due to the lack of IL-1 receptor type I are protected against ovariectomyinduced bone loss (368). Treatment with IL-1ra decreased bone resorption (11) and prevented bone loss in ovariectomized rats (10) . The essential role of TNF-␣ in ovariectomyassociated bone loss is suggested by the finding that treatment of ovariectomized mice with TNF-␣ binding protein, a potent inhibitor of TNF-␣, completely prevented bone loss (11, 369). Likewise, transgenic mice insensitive to TNF-␣ due to the overexpression of soluble TNF receptor (370), as well as rats receiving an orally active inhibitor of IL-1 and TNF production (371) , have been shown to be protected against bone loss with ovariectomy. Increases in osteoclast numbers in vitro and in vivo in ovariectomized mice were also prevented by an antibody to IL-6 (Refs. 9 and 372 and Fig. 5 ). In accordance, IL-6-knockout mice are protected against the loss of trabecular bone induced by ovariectomy (373) . The critical involvement of PGs is supported by the findings that the nonsteroidal COX inhibitor naproxen inhibited bone loss induced by up to 70% ovariectomy in rats (374) . T cell deficiency also effectively prevented bone loss in ovariectomized mice (199) .
Of interest is that IL-1␤-deficient mice do not appear to be protected against ovariectomy-induced bone loss (375) . Thus, simultaneous suppression of both the IL-1␣ and IL-1␤ genes may in fact be required for blocking bone loss with estrogen deficiency. Moreover, some of the requirements of cytokines for bone loss, at least in these animal models, appear to change with time after estrogen withdrawal. Whereas simultaneous treatment with IL-1ra and the TNFbinding protein was required to completely prevent the bone loss and increase in bone resorption in the first month after ovariectomy (376), IL-1␣ alone was sufficient to prevent bone loss in the following months (10). As outlined above, bone loss with estrogen deficiency involves a large number of interrelated changes in estrogendependent regulatory factors (377) . In contrast to other proinflammatory conditions such as inflammatory arthritis, in which the deficiency in single proinflammatory cytokines does not fully prevent the inflammatory process (378), deficiency in each of the above cytokines is sufficient to completely block excessive bone resorption with estrogen deficiency. Miyaura et al. (379) showed that the endogenous bone-resorbing activity present in bone marrow supernatants from ovariectomized mice was only equaled by the concurrent addition of IL-1, IL-6, sIL-6R, and PGE 2 in those concentrations that were present in bone marrow supernatants, suggesting that the full extent of bone resorption in this in vitro system was only achieved by the additive effects of these factors. However, it should be pointed out that the central role of cytokines for bone loss with estrogen deficiency does not exclude the possibility that additional cytokine-independent changes in bone metabolism may also be among the determinants of postmenopausal bone loss. For example, there is an increasing body of evidence supporting direct, cytokine-independent effects of estrogen on osteoclast and osteoblast function (380 -384) . Some of the postmenopausal changes in bone metabolism may also result from the loss of extraskeletal effects of estrogen on calcium homeostasis (6) and IGF-I synthesis (253, [385] [386] [387] [388] [389] [390] [391] [392] [393] .
Despite the impressive prevention of ovariectomyinduced bone loss by neutralizing each single cytokine involved in this process, in most of the above animal studies bone resorption was normal in the animals that were not deficient in estrogen, indicating the particular role of the changes in these cytokines and cellular components in bone loss with estrogen deficiency. The redundancy of the function of most of these cytokines for osteoclast formation may compensate the lack of function of each of these components in situations apart from estrogen deficiency. The clear exceptions are M-CSF and the components of the RANKL/ OPG/RANK system, whose activity is essential for osteoclast generation (199, 230, 317, 394 -396) .
C. Evidence for a role of cytokines in human bone loss after menopause
Most of the evidence for a causal involvement of proinflammatory cytokines in bone loss with estrogen deficiency has been obtained in rodents. However, as bone metabolism in rodents differs in many ways from that in humans, it is not certain that these pathways will also prove to be as important in humans. In fact, evidence that proinflammatory cytokines play a similar decisive role in postmenopausal human bone loss is still very limited. Arguing in favor of a similar mechanism in humans are findings that the enhanced capacity of monocyte cultures from postmenopausal women to stimulate bone resorption in vitro correlated with the levels of IL-1, IL-6, and TNF-␣ in the conditioned medium and could be blocked by the addition of IL-1ra and anti-TNF antibody (397) . Ralston et al. (33) demonstrated that IL-1, TNF, and IL-6 mRNAs are expressed more frequently in bone cells from untreated postmenopausal women than in those from women on estrogen replacement. There are preliminary reports that serum OPG levels may be associated with bone mineral density [BMD (398) ], but these findings have not been confirmed by a subsequent study (235). Further evidence for a specific role of proinflammatory cytokines as a determinant of human postmenopausal bone loss comes from the Heidelberg cohort of the European Vertebral Osteoporosis Study [EVOS (399) ]. In this study, serum IL-6 strongly and specifically predicted femoral bone loss in early postmenopausal women. In fact, serum IL-6 was the single most important predictor of early postmenopausal bone loss, accounting for up to 34% of the total variance of change in BMD in the first few years after menopause. This is, however, in contrast to a study of peri-and postmenopausal Danish women, in which high circulating IL-6 levels were associated with slower spinal bone loss (77). Associations in the latter study were weak, but these discrepancies clearly point out the necessity for further studies.
VIII. Potential Implications for Vascular
Function (Fig. 4) The risk of cardiovascular disease strongly increases after menopause (3) . Data from the United States show that, by the age of 60 yr, only 1 in 17 women has had a coronary event, as compared with 1 in 5 men. After the age of 60, however, coronary heart disease is the primary cause of death among women in Western countries. Epidemiological and casecontrolled studies consistently suggest that postmenopausal women have about a 50% reduction in cardiovascular disease with estrogen administration (400). Ross and Glomset (401) proposed the "response to injury" hypothesis for the pathogenesis of atherosclerosis some 25 yr ago, leading the way to the now widely acknowledged active role of inflammation in this disease. During the last decade, it has indeed become increasingly evident that atherosclerosis manifests many of the characteristics of an inflammatory response (402) (403) (404) . Inflammatory parameters such as IL-6-dependent C-reactive protein are strong predictors of cardiovascular events and cardiovascular mortality in postmenopausal women (405) (406) (407) (408) (409) . Many of the cytokines whose activity is altered with menopause are thought to be involved in the process of atherogenesis. Thus, IL-1, TNF-␣, and IL-6 are all secreted in the vascular wall by endothelial cells, smooth muscle cells, and monocytes/macrophages (403, 410 -412) . These cytokines can increase the permeability of the endothelial cell barrier and can induce the expression of surface leukocyte adhesion molecules and, thus, may be acting already very early on in the pathogenesis of atherosclerosis. Estrogen also down-regulates monocyte chemotactic protein-1, which mediates the recruitment of macrophages to the arterial wall (413) . IL-1 stimulates the secretion of platelet-derived growth factor, which in turn acts as a mitogen for smooth muscle cells and fibroblasts and may serve as a mediator in the invasion of the damaged vessel intima by hypertrophic smooth muscle (414) . The adhesive interactions between endothelial cells and recruited inflammatory cells can again signal the production of other cytokines and growth factors, with all such activities being considered to promote atherosclerosis. Cytokine-induced NF-B activity mediates the expression of matrix metalloproteinases, which may promote plaque instability and rupture. Expression of IL-6 in atherosclerotic plaques seems to be elevated compared with normal intima (415) . Strong evidence for a causal role of proinflammatory cytokines in the pathogenesis of atherosclerosis is also derived from the use of neutralizing antibodies against proinflammatory cytokines in animal models. For example, blocking IL-1 and TNF action by using IL-1ra or TNF-binding protein, respectively, inhibited fatty-streak formation in ovariectomized apolipoprotein E-deficient female mice (Ref. 416 and Fig. 6 ). Mice that are homozygous for a null mutation of IL-1ra develop lethal arterial inflammation (417) . Further evidence for a causal role of IL-6 in the development of atherosclerosis is provided by the findings that C57BL/6 and apolipoprotein-E-deficient mice show a progression of atherosclerotic lesions with weekly injections of IL-6 (418). Down-regulation of OPG and TGF-␤ with menopause may also negatively affect vascular homeostasis (419 -422) . In particular, OPG appears to be a critical factor for endothelial cell survival (229), which is clearly supported by the findings that mice deficient in OPG exhibit calcification of the aorta and renal arteries (230, 231).
In summary, there is some reason to believe that changes in proinflammatory cytokines with menopause may also have long-term detrimental effects on vascular function and may contribute to atherosclerosis in postmenopausal women. A direct relationship between atherosclerosis, IL-6, and estrogen deficiency was revealed by the finding that IL-6 mRNA and protein are overexpressed in the atherosclerotic plaques of apolipoprotein-E-knockout mice and that this IL-6 production was suppressed by 17␤-E2 treatment in this apolipoprotein-E-knockout mouse model of atherosclerosis (46). However, in contrast to the changes in bone resorption after menopause, IL-6 does not appear to constitute an essential target for E2 to prevent fatty-streak formation, as estrogen supplementation decreased fatty streak formation in a similar way in apolipoprotein-E-knockout mice with an intact and nonfunctioning IL-6 gene (423) . In analogy to bone tissue, part of the anti-inflammatory effects of estrogen may be mediated by an inhibitory effect on lymphocyte maturation. Studies in lymphocyte-deficient atherosclerosis-prone recombination activating gene 1/low-density lipoprotein receptor-double knockout mice suggested that lymphocytes play an important role in lesion initiation and early progression (424) . Both lymphocyte depletion and estrogen-substitution reduced lesion size in the aortic root to a similar extent in ovariectomized apolipoprotein-E-deficient mice. Interestingly, no additional atheroprotective effects were provided by combining estrogen replacement and lymphocyte depletion (425), providing further tentative clues for an interrelated pathway of the immune system and estrogen action on vessel function.
Nevertheless, in contrast to bone tissue, the number of studies that have addressed the role of proinflammatory cytokines in vascular dysfunction with menopause are still extremely limited, precluding a more definitive conclusion on the relevance of these effects to the atheroprotective actions of estrogen at the present time.
IX. Individual Susceptibility to Estrogen-Dependent Cytokine Changes
In humans, menopause-related metabolic changes in the skeleton can be easily monitored by the means of sequential BMD measurements. These measurements have revealed that the rate and extent of bone loss after menopause varies widely between individuals, with some women losing bone quickly and others losing it slowly. It is of course attractive to postulate that this may be in part due to individual differences in cytokine activity. The most obvious explanation may be an inverse association of cytokine activity with the declining serum estrogen concentrations. In support of this, Chiu et al. (426) have observed a negative correlation between circulating IL-6 and E2 concentrations during the normal menstrual cycle. In contrast, no such association was present in early postmenopausal women who took part in the EVOS study (399) , suggesting that once a certain lower threshold of estrogen concentrations has been reached, the residual estrogen concentrations may cease to be a major determinant of individual differences in cytokine activity.
Because most of the currently known interactions between estrogen and cytokines in nonreproductive tissues at the molecular level are indirect, and estrogen therefore appears to play the role of a gatekeeper of cytokine activity, a decline in estrogen may allow for a better efficiency of preexisting proinflammatory stimuli to stimulate cytokine expression. In other words, the magnitude of the postmenopausal increase in proinflammatory cytokine production may depend to a great extent on the proinflammatory stimuli that are present in the cellular environment at the time of menopause. Based on this hypothesis, the consequences of estrogen deficiency may be small, if few such stimuli are present or if the stimuli are so strong as to overcome the mildly suppressive effects of estrogen. It may be the "in-between" situation, in which estrogen might exert its greatest impact on cytokine activity. For example, Rogers and Eastell (38) observed an inhibitory effect of physiological concentrations of E2 on spontaneous proinflammatory cytokine release from whole-blood cultures, but not after cytokine secretion had been stimulated with lipopolysaccharide. The most common physiological stimuli for cytokine expression are oxygen-derived free radicals (427) , which are inevitable byproducts of normal biological functions such as respiration or energy generation. Free radical-derived advanced glycation end products and other inflammatory mediators, via binding to the advanced glycation end products receptor (428) , hypoxia (429) , and chronic subclinical infections (430, 431) , are examples of nonphysiological stimuli that may determine cytokine expression. Estrogen withdrawal has been shown to augment PTHinduced IL-6 production in vitro and in vivo (432) . This raises the hypothesis that differences in PTH secretion, which again to a large extent reflect differences in calcium and vitamin D status, may also be a potential and physiologically relevant determinant of the susceptibility to menopause-related increases in IL-6 in bone tissue and perhaps in other tissues as well. In bone cells, early responses to strain and estrogen have been described to share a common pathway, which involves ER-␣ (433), making it tempting to speculate that differences in ER-␣ activation by strain may also determine postmenopausal cytokine production. Apart from identifying stimuli that may determine the extent of cytokine changes with menopause, it will, of course, also be of great interest to identify endogenous and environmental factors that may protect against increases in proinflammatory cytokines in postmenopausal women.
On the response side, a number of cytokine genes and genes involved in inflammatory responses are polymorphic and may be important for defining the magnitude of the individual responses to a given environmental stimulus of cytokine production. The list includes genes that affect cytokine expression, binding of cytokines to their receptors, genes involved in the cytokine signaling pathways, and many others. There is a growing number of studies that have examined the effects of these cytokine polymorphisms on postmenopausal bone loss. Tsukamoto et al. (434) investigated an association between a CA-repeat polymorphism at the IL-6 gene locus and BMD of radial bone in 472 postmenopausal Japanese women. The 73 women who possessed an A1 allele (134 bp, containing 18 repeats of CA) had significantly lower BMD than those who did not carry an allele of that size. Keen et al. (435) examined the relationship between annual rates of change in BMD and an 86-bp variable number tandem-repeat polymorphism of the IL-1ra gene in 108 women without hormonal replacement therapy within 5 yr of menopause. They observed that carriage of at least one copy of the A2 allele was associated with reduced bone loss at the spine. Langdahl et al. (436) also showed that genotypes associated with a low IL-1ra production (A1A1/A3) were significantly more frequent in women with osteoporotic fractures compared with normal individuals, but this polymorphism had no effect on bone loss in another study of 487 postmenopausal Danish women (437) . Data from our group from the EVOS study have shown a 2-fold increase in circulating IL-6 levels in early postmenopausal women with a CC genotype of the G-to-C polymorphism at position Ϫ174 of the IL-6 promoter, compared with women with the GG phenotype. Higher circulating IL-6 levels in this study corresponded to increased rates of bone loss (C. Clanget and J. Pfeilschifter, unpublished data). In contrast, in postmenopausal healthy women, serum levels of C-telopeptide of type I collagen, a marker of bone resorption, were significantly higher in women with the GG phenotype compared with women with the GC and CC genotype. This was associated with a tendency for a higher BMD at the hip and forearm in CC subjects compared with the GG subjects (438). Jones et al. (439) again reported a strikingly lower cardiovascular and all-cause mortality for individuals of GG genotype compared with those of GC and CC genotype. There are other studies that have observed associations between cytokine polymorphisms and coronary artery disease (249), although none of these data have been evaluated in the context of early postmenopause.
With respect to TGF-␤, a 1-base deletion in intron 4 (713-8delC) of the TGF-␤1 gene has been associated with low BMD, increased bone turnover, and an increased rate of fragility fractures in osteoporotic Danish and Italian women (440, 441) . In postmenopausal Japanese women, the CC genotype of a T/C polymorphism at nucleotide 29 in the signal sequence of the TGF-␤1 gene has been observed to be associated with lower spinal bone loss, fewer vertebral fractures, and lower circulating levels of TGF-␤1 compared with women with the TC or TT genotype (442) (443) (444) , but the latter findings could not be confirmed in postmenopausal Caucasian women by our own group (445) .
It should be cautioned that these association studies are subject to a high rate of spurious results. Most of the existent data suffer from small numbers, lack of reproducibility, and lack of knowledge about the functional significance in terms of the effect of the variant on transcriptional activity. Moreover, despite their potential influence on the extent of cytokine changes after menopause, the strength of each of these phenotypic variations as a single determinant of cytokine activity may be rather modest.
X. Time Course of Cytokine Increases after Menopause
A fascinating aspect of metabolic changes with estrogen deficiency is that they may, in fact, be limited in time. The most prominent examples for this are hot flashes, which in most women abate within the first 5-10 yr after menopause (446) . It is also well established that the accelerated phase of bone loss is limited to the first 5-10 yr following menopause (271). Of note, this temporal limit in rapid bone loss after menopause appears to be closely related to temporal changes in proinflammatory cytokine activity. In the Heidelberg cohort of the EVOS study (53), the predictive effect of circulating IL-6 levels on postmenopausal femoral bone loss was limited to the first decade past menopause. Consistent with this, Pacifici et al. (447) observed that the production of IL-1␤, the ratio of IL-1␤ to IL-1ra, and IL-1 bioactivity in monocyte cultures were all increased in the first years after menopause but declined to within the premenopausal range thereafter. Moreover, levels of IL-1, TNF, and IL-6 in bone marrow cultures from early postmenopausal women were higher compared with those from premenopausal women, but there was no difference in these cytokine levels between late postmenopausal women and premenopausal women, again suggesting confinement of cytokine increases to the fist years after menopause (Ref. 12 and Fig. 7) .
As the precise mechanisms that are responsible for cytokine changes with menopause are still a matter of intense investigation, it may not be surprising that the transient nature of these cytokine increases is even less understood. Inflammatory conditions tend to increase age independently from menopause (448, 449), and it is thus possible that ageassociated increases in proinflammatory cytokines may simply dilute the impact of menopause on cytokine metabolism. On the contrary, it is also possible that age-related changes in cellular function, and particularly in immune cell function, may compensate for the intracellular pathways that are activated by estrogen deficiency, including estrogen-independent activation of the ER itself (450). Pointing in this direction, Bruunsgaard et al. (451) observed an age-related decline in the production of proinflammatory cytokines in wholeblood supernatants in response to lipopolysaccharides. Wang et al. (32) observed that 17␤-E2 inhibited IL-1␤ mRNA expression in vitro only in osteoblastic cells derived from young mice, but not from old mice, further indicating that aging may directly modulate estrogen-dependent modulation of IL-1. Arguing against this are findings by Bismar et al. (12), who observed elevated proinflammatory cytokine production by human bone marrow cells not only immediately after natural menopause, but also upon withdrawal from long-term estrogen replacement therapy (Fig. 7) . However, the women in this study were still relatively young when they stopped hormonal replacement therapy, and it remains to be established whether similar cytokine increases might also occur in older women.
XI. Role of Progesterone
With menopause, there is not only a decline in endogenous estrogen, but also in gestagens. Our knowledge about the role of natural progesterone in menopause-related changes in tissue function is, however, far more limited, because most of the clinical studies that have looked at the effects of gestagens on postmenopausal tissue metabolism alone or in combination with estrogen have been conducted with synthetic gestagen compounds, which are known to counteract some of the beneficial effects of estrogens on lipid metabolism (452, 453). With respect to postmenopausal cytokine changes, progesterone in many cases appears to act in a similar way to estrogens. Low physiological doses of progesterone have been shown to increase human or rat macrophage and monocyte IL-1 and TNF-␣ production, whereas higher doses suppressed cytokine release and IL-1 mRNA expression (36, 454). As with the ER, mutually repressive effects of NF-B and progesterone receptor transactivation have been described (455). Clinical studies using progesterone to prevent bone loss have found variable results, with some studies showing an effect of progesterone in prevention of spinal or cortical bone loss and other studies finding little benefit of progesterone treatment on postmenopausal bone loss (383, 456) . With respect to the interactions between progesterone and cytokine metabolism in nonreproductive tissues, many gaps still remain to be filled.
XII. Role of Androgens
The effect of the menopausal transition on circulating androgen levels has been addressed in several studies with variable results. Longitudinal measurements of circulating androgen concentrations in peri-and early-postmenopausal women suggest that the free androgen index, calculated as the ratio of T to sex hormone binding globulin increases by 80% from 4 yr before the final menstrual period to 2 yr after the final menstrual period (457). This may be, in part, due to an estrogen-related decline in sex hormone binding globulin, but also in part to a small decline in T production during the first years after menopause (457-459). The adrenal androgen dehydroepiandrosterone (DHEA) and its sulfate conjugate (DHEAS), which are the major source of circulating and tissue estrogen concentrations after menopause (460, 461), clearly decrease in postmenopause. However, relative to menopause, this is as a function of age rather than of time (457, 462).
An increasing body of evidence suggests that androgen deficiency may up-regulate proinflammatory cytokines in a way similar to estrogen deficiency. T deficiency induced IL-6 protein synthesis and mRNA expression in the bone marrow (463). T inhibited IL-6 expression and/or production by human osteoblastic cells (464), bone marrow stromal cells (42), human gingival fibroblasts in vitro (465), prostate carcinoma cells (466), HeLa cells (43), and peripheral blood mononuclear cells (467). T also inhibited the expression of the IL-1 gene in murine bone marrow-derived stromal cells through the AR (468). Orchidectomized IL-6-deficient mice do not lose bone, suggesting that IL-6 is involved in bone loss caused by androgen deficiency in a similar way as in bone loss with estrogen deficiency (464, 468).
With respect to DHEA, there is an inverse relationship between plasma DHEA levels and circulating IL-6 levels (469, 470). Inhibitory effects of DHEA on IL-6 and/or TNF-␣ production have been observed in spleen cell suspension cultures (469), lymphocytes (471, 472), astrocytes (473) , and peripheral blood mononuclear cells (470, 474). DHEA/ DHEAS have also been shown to inhibit circulating concentrations of TNF-␣ (475) and IL-6 (476) in rodents.
The similarity between estrogen and androgen effects on cytokine production is even evident in those experimental designs, in which estrogen stimulated rather than inhibited cytokine production. Thus, both T and E2 synergized with IL-1 in the induction of IL-6 in cultures of human articular chondrocytes (477) and increased IL-1␤ mRNA levels in hu- FIG. 7 . Differences in the concentrations of IL-1-␣, TNF-␣, and IL-6 in 48-h-conditioned medium from human bone marrow cultures with time after estrogen withdrawal. Cells were either obtained from premenopausal women (n ϭ 12), early-postmenopausal women less than 5 yr since menopause (n ϭ 5, "Early post"), women who had recently discontinued estrogen replacement (n ϭ 5, "Disc. estrogen"), or latepostmenopausal women more than 8 yr since menopause (n ϭ 18, "Late post"). Data are mean Ϯ SE. *, P Ͻ 0.05. [Derived from Ref. 12.] man osteoblastic cells (478) . Although androgens and estrogen have many different effects on T and B cell function (195) , they appear to share repressive effects of B lymphopoiesis (203, 479) . Moreover, like estrogen, androgens block PGE 2 production (480) and stimulate TGF-␤ activity (481, 482) .
Many of the effects of DHEA and T on bone and vascular tissue appear to be mediated by their aromatization to estrogen (483, 484) . Part of their inhibitory effects on proinflammatory cytokine concentrations may thus be secondary to the suppressive effects of estrogen on these cytokines. However, suppressive effects of androgens on proinflammatory cytokine activity have also been observed with 5-␣-dihydrotestosterone (465, 485), which is a nonaromatizable androgen, suggesting that direct inhibitory effects are also involved. Clinical data by Falahati-Nini et al. (484) show that in men, these direct effects of androgens, which are not mediated by aromatization to estrogen, may account for at most 30% of the increase in bone resorption that is observed with combined androgen and estrogen deficiency. Given the homology between the ER and the AR, the molecular mechanisms for the direct suppressive effects of androgens on cytokine expression may be similar to that described for estrogen (86). In support of this hypothesis, inhibitory effects of DHEA on the activation of the IL-6-promoter have been found to involve NF-B-DNA complex formation (466, 485). The direct effects of the weaker androgens, DHEA and DHEAS, on cytokine expression also appear to be mediated by the AR, as suggested by DHEAS-induced repression of the IL-6 promoter in HeLa cells when transfected with the AR (468).
In view of the remarkable similarity between androgens and estrogen with respect to cytokine suppression, one would predict that these steroids may also be exchangeable in preventing cytokine-induced tissue damage. Indeed, in a model of inflammation-induced cartilage degradation in female rodents, ovariectomy resulted in accelerated cartilage breakdown associated with increased production of IL-1, and the effects on cartilage were reversed by treatment with E2 or T (486). In contrast, plasma levels of IL-6 and TNF-␣ in male, but not female, mice increased after hemorrhage and subsequent sepsis, and there only was an increased mortality in male mice as compared with sham-treated animals. Thus, there appear to be distinct sex differences in the inflammatory responses, which may either be due to some concentration-dependent function of androgens that cannot be replaced by estrogen and vice versa or to sex hormoneindependent mechanisms that remain to be identified (487) .
The impact of the decrease in adrenal androgens in postmenopausal women on proinflammatory cytokine activity is currently unknown. Nevertheless, inhibition of aromatization in postmenopausal women is associated with an increase in bone resorption, and there is increasing evidence for a protective role of DHEA with respect to elevated bone resorption and osteoporotic fractures in postmenopausal women (488, 489) . It will be interesting to find out whether part of these effects may be related to changes in proinflammatory cytokine activity. Decreases in T may be of particular relevance after surgically induced menopause, as the ovaries are an important source of T, and serum T concentrations decline by 50% after bilateral oophorectomy both in pre-and postmenopausal women (458, 490).
XIII. Potential Implications for the Prophylaxis of Menopause-Associated Diseases
Treatment strategies for the use of prophylactic medications for the prevention of menopause-associated diseases may greatly gain in feasibility if it is possible to better predict who will benefit most from such medication, particularly because widespread screening for menopause-associated disorders is problematic in terms of validity and cost. The findings that circulating IL-6 levels predict femoral bone loss in early postmenopausal women (399) and that IL-6-derived C-reactive protein strongly predicts the development of symptomatic coronary artery disease (407) make these measurements attractive parameters for the identification of high-risk groups of early postmenopausal women, although the clinical utility of these measurements clearly needs to be assessed in larger studies.
In line with the increasing shift of medicine away from the treatment of acute symptoms to the prophylaxis of complex chronic disorders, the major emphasis of health care after menopause is also shifting from the immediate relief of postmenopausal symptoms to the prophylaxis of menopauseassociated chronic diseases. However, the long interval between the initiation of prophylactic treatment and the occurrence of clinical events that has to be passed until the benefits of treatment can be assessed makes it increasingly important to take into account all cellular and molecular changes that may eventually occur with treatment before embarking on costly long-term studies. In view of the emerging role of inflammation as an important component in the pathogenesis of menopause-related disorders, it may be worthwhile to include the effects of treatment on proinflammatory cytokine activity into these considerations.
Estrogen is not the only compound that may be useful to combat detrimental effects of cytokine increases associated with menopause. Breast-and uterine-related side-effects are principal causes for noncontinuation of conventional hormone replacement therapy. Drugs that avoid the side-effects of natural estrogen may be equally or even better-suited to achieve this goal. The search is therefore on for chemists to create molecules that distinguish between estrogen not at the level of binding but, rather, by the complement of coactivators and corepressors that are recruited to the ligand-bound ER. This goal appears to have been at least in part accomplished with the SERMs, a new and fascinating class of drugs that reverse menopause-associated cytokine changes in a similar way as natural estrogen, but avoid many unwarranted effects that are associated with binding of estrogen to its classical EREs in reproductive tissues.
Compounds that directly interact with cytokine activity may be even more effective in neutralizing menopauserelated cytokine changes. Indeed, one might speculate that, because many of the interactions between cytokines and estrogen are mutual (491) , potent stimuli of proinflammatory cytokines might render estrogen or SERMs rather insufficient in suppressing cytokine activity. Efforts to develop IL-6-secretion inhibitors or small molecule antagonists to IL-6 are currently underway and might be a promising way for the systemic amelioration of all postmenopausal dysfunctions in which IL-6 is involved.
There are a number of drugs already in use for the treatment of metabolic disorders, whose clinical response may in fact be partially due to their anti-inflammatory effects (492, 493) . For example, this seems to apply to the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) that have been convincingly shown to decrease the risk of coronary heart disease (494). The potent anti-inflammatory actions of these drugs is clearly illustrated by the observation that pretreatment of mice with cerivastatin counteracted lipopolysaccharide-triggered increases in circulating TNF-␣ and IL-1␤ and improved survival (495). In men, treatment with pravastatin for 8 wk also significantly reduced circulating TNF-␣ concentrations (496).
Ligands of PPAR␣, such as fenofibrate, also inhibit inflammatory responses by repressing NF-B signaling. As a consequence, hyperlipidemic patients treated with fenofibrate have reduced circulating levels of IL-6, TNF-␣, and acute-phase proteins (497, 498). Ligands of PPAR-␥, such as the thiazolidinediones, which have been developed for clinical use because of their capacity to increase sensitivity to insulin (499), decrease the expression of cytokines, such as TNF-␣, IL-1, and IL-6, in monocytes and smooth muscle cells (500, 501), a mechanism that is mediated via inhibition of the AP-1 and NF-B cytokine-inducing pathways outlined above (502). Plasma levels of TNF-␣ and C-reactive protein significantly declined in obese individuals who were given 400 mg of the thiazolidinedione troglitazone for 4 wk (501, 503). In turn, proinflammatory cytokines such as TNF-␣, IL-1, and IL-6 are able to decrease PPAR-␥ mRNA expression (504).
In fact, the thiazolidinediones already have a range of actions as broad as that observed with estrogen, because they not only affect glucose metabolism but also appear to be potent inhibitors of cytokine-mediated bone resorption (505, 506) and may have beneficial effects in preventing atherosclerotic lesions (502). It is tempting to speculate that at least part of these systemic effects may be due to their cytokineantagonistic effects. Indeed, in a recent study, the PPAR-␥-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in male low-density lipoprotein receptor-deficient mice, and this antiatherogenic effect was correlated with decrease tissue expression of TNF-␣ (507).
XIV. Summary and Conclusions
Bone metabolism and vascular function are determined throughout life by a multitude of genetic and environmental influences that appear to have little in common. The pathogenesis of chronic disorders of these tissues is complex, but there is increasing support from experimental and clinical studies that the development of these disorders may be in part linked to an increased state of proinflammatory activity. Because estrogen has been shown to modulate proinflammatory cytokine activity, it is tempting to speculate that, for a limited period of time after menopause, women who are susceptible for environmental or genetic reasons may experience a progression or initiation of diverse diseases such as osteoporosis and coronary heart disease, triggered by a systemic change in the balance of proinflammatory cytokine activity. In contrast to the predominantly genomic effects of estrogen on reproductive tissues, most of the actions of estrogen on cytokine activity in nonreproductive tissues appear to be mediated by nongenomic mechanisms. They potentially include antagonistic effects of activated ERs on proinflammatory transcription factors, modulation of NO activity, direct antioxidative effects, and secondary effects due to estrogen actions on the immune system. Assessment of cytokine activity or of related products after menopause may help to identify those women who are at increased risk to experience detrimental metabolic effects in early postmenopause. Understanding the mechanisms and the time course of these interactions may also open new avenues for the prophylaxis and treatment of some of the most prevalent and important disorders in elderly women. Nevertheless, much of the evidence available at this time is suggestive rather than definitive. Continued efforts both at the workbench and in clinical research will be necessary to determine the ultimate impact of these interactions for postmenopausal health. 
